Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.9%

6 terminated out of 55 trials

Success Rate

79.3%

-7.2% vs benchmark

Late-Stage Pipeline

22%

12 trials in Phase 3/4

Results Transparency

30%

7 of 23 completed with results

Key Signals

7 with results79% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (16)
Early P 1 (2)
P 1 (4)
P 2 (6)
P 3 (3)
P 4 (9)

Trial Status

Completed23
Unknown9
Recruiting8
Terminated6
Withdrawn6
Active Not Recruiting1

Trial Success Rate

79.3%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (55)

Showing 20 of 20 trials
NCT07352800Phase 2RecruitingPrimary

Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

NCT06832631Recruiting

VITUS Post-Market Registry

NCT04007055Phase 3Terminated

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

NCT06319339Early Phase 1Recruiting

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

NCT07093632CompletedPrimary

Medium-term Results of Lower Limb Arterial Bypass

NCT06056193Not ApplicableWithdrawnPrimary

The SIR-POBA Bypass Trial

NCT06980064Not ApplicableNot Yet Recruiting

Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations

NCT02460042Active Not RecruitingPrimary

Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW)

NCT06204237Early Phase 1RecruitingPrimary

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

NCT05961943Not ApplicableRecruiting

RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients

NCT05586022RecruitingPrimary

Risk Factors for Adverse Outcomes of Endovascular Revascularization in Lower Extremity Arteriosclerosis Occlusion

NCT06082466Not ApplicableRecruitingPrimary

FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial

NCT03933657Not ApplicableWithdrawnPrimary

Prospective Study of the SoundBite™ Crossing System in Complex Peripheral CTOs

NCT02189018Not ApplicableCompletedPrimary

Activity To Improve Outcomes in Peripheral Arterial Disease

NCT01855412CompletedPrimary

Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes

NCT05933720Not ApplicableRecruitingPrimary

Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.

NCT04083755Phase 4Unknown

Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD)

NCT05616169Unknown

The EasyFlype/EasyHiFlype Post Market Clinical Follow-up Study.

NCT05590182Not ApplicableCompletedPrimary

CO2-Angiography-Study to Evaluate Diagnostic and Safety to Patients With Peripher Arterial Stenotic or Occlusive Disease.

NCT02832570Phase 3CompletedPrimary

Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication

Scroll to load more

Research Network

Activity Timeline